Teladoc Health (TDOC)
(Delayed Data from NYSE)
$7.17 USD
+0.07 (0.99%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $7.18 +0.01 (0.14%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.17 USD
+0.07 (0.99%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $7.18 +0.01 (0.14%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth C Momentum A VGM
Zacks News
Here's Why Teladoc (TDOC) Gained But Lagged the Market Today
by Zacks Equity Research
In the closing of the recent trading day, Teladoc (TDOC) stood at $7.17, denoting a +0.99% change from the preceding trading day.
Masimo's (MASI) W1 Watch Gains FDA Nod for SafetyNet Connectivity
by Zacks Equity Research
The latest FDA clearance of Masimo's (MASI) W1 medical watch is likely to provide a continuous and accurate view of patients' health data.
Hims & Hers (HIMS) Gains 45.8% in Three Months: What's Next?
by Debanjana Dey
Hims & Hers (HIMS) is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.
Teladoc Health (TDOC) Shares Down 8.9% Despite Q2 Earnings Beat
by Zacks Equity Research
Teladoc Health (TDOC) expects revenue growth in the Integrated Care segment to be within low to mid-single-digit growth in 2024, on a year-over-year basis.
Teladoc (TDOC) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Teladoc (TDOC) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Teladoc (TDOC) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Teladoc (TDOC) delivered earnings and revenue surprises of 22.22% and 1.06%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Can Teladoc (TDOC) Q2 Earnings Navigate BetterHelp Profit Woes?
by Zacks Equity Research
Teladoc's (TDOC) second-quarter results are likely to reflect lower advertising and marketing expenses.
Countdown to Teladoc (TDOC) Q2 Earnings: Wall Street Forecasts for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Teladoc (TDOC), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
Teladoc (TDOC) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
Teladoc (TDOC) closed the most recent trading day at $9.30, moving +1.2% from the previous trading session.
Teladoc (TDOC) Ascends But Remains Behind Market: Some Facts to Note
by Zacks Equity Research
Teladoc (TDOC) closed the most recent trading day at $9.39, moving +0.21% from the previous trading session.
Hims & Hers (HIMS) Gains 37.7% in Three Months: What's Next?
by Debanjana Dey
Hims & Hers (HIMS) is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.
Teladoc (TDOC) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
Teladoc (TDOC) closed at $10.14 in the latest trading session, marking a -0.1% move from the prior day.
Teladoc (TDOC) Harnesses AI for Diabetes Care, Stock Rises 6.7%
by Zacks Equity Research
AI can help Teladoc (TDOC) to streamline healthcare delivery, making it more efficient and scalable.
Teladoc (TDOC) Soars 6.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Teladoc (TDOC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Teladoc (TDOC) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Teladoc (TDOC) concluded the recent trading session at $10.11, signifying a +1.1% move from its prior day's close.
Teladoc (TDOC) Rises Yet Lags Behind Market: Some Facts Worth Knowing
by Zacks Equity Research
Teladoc (TDOC) concluded the recent trading session at $10.66, signifying a +0.19% move from its prior day's close.
Teladoc (TDOC) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
In the most recent trading session, Teladoc (TDOC) closed at $10.87, indicating a -1.9% shift from the previous trading day.
Elevance Health (ELV) Stock Jumps 6.1%: Will It Continue to Soar?
by Zacks Equity Research
Elevance Health (ELV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Teladoc (TDOC) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
In the closing of the recent trading day, Teladoc (TDOC) stood at $11.15, denoting a -1.85% change from the preceding trading day.
Here is What to Know Beyond Why Teladoc Health, Inc. (TDOC) is a Trending Stock
by Zacks Equity Research
Teladoc (TDOC) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Teladoc Health (TDOC) Q1 Loss Widens on Decline in Visits
by Zacks Equity Research
Teladoc Health's (TDOC) Q1 results suffer from weak contributions from the BetterHelp unit. Management expects U.S. Integrated Care Members of 92-94 million for 2024, up from the prior mentioned 90-92 million.
Teladoc (TDOC) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Teladoc (TDOC) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Teladoc (TDOC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Teladoc (TDOC) delivered earnings and revenue surprises of -4.26% and 1.44%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Can Higher Visits Soften Cost Blow for Teladoc (TDOC) in Q1?
by Zacks Equity Research
Teladoc's (TDOC) first-quarter results are expected to have benefited from higher visits. However, high costs might have partially offset the positives.
Analysts Estimate Teladoc (TDOC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Teladoc (TDOC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.